Submissions

Online Submissions

Already have a Username/Password for Medical academic journal?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required for submitting items online, and for checking the status of current submissions.

 

Author Guidelines

Preparing the manuscript, authors are kindly requested to adhere to the following guidelines based on the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors.

The Editorial team emphasizes the need for strict adherence to the guidelines for manuscript formatting and submission. It may reject manuscripts if the authors fail to meet the requirements below.

The Editorial Office only considers original works for publication. The authors should only submit manuscripts that have not been previously published or submitted elsewhere.

 

I. Formal Procedures


Submission of Manuscripts and Files; Editorial Communication

All manuscripts, supporting or supplementary materials, or revised versions should be submitted exclusively (!) via the Editorial Management System to the Editorial Office.

PLEASE NOTE: The Editorial Office only accepts manuscripts uploaded via the Editorial Management System on the journal’s official website. Manuscripts submitted via email or in any other way will be rejected. Do not submit any materials via email. Upload them to the Editorial Management System first.


One of the authors should log in or sign up to the Editorial Management System on the journal’s website. All contributing authors are encouraged to sign up on the journal’s website.

The manuscript submission process involves several steps:

  • Step 1. Select the appropriate journal section and the submission language. Next, carefully read through the Submission checklist. Check all the points to confirm them.
  • Step 2. Upload your full-text manuscript file.
  • Step 3. Upload all the supporting documents and supplementary files.
  • Step 4. Provide as much information as possible about each (!) author. Please list the authors in the correct order. All the authors should be listed at submission.
  • Step 5. Enter the relevant metadata in the designated fields: Title, Abstract, Keywords, Funding Sources, and References.
  • Step 6. Copy and paste your manuscript into the Article Full Text field.
  • Step 7. Carefully review the APC-related information, including mandatory and optional fees, payment terms, payment methods, and waiver policy.
  • Step 8. Click the Finish Submission button to finalize your submission. The manuscript will not be submitted without this step.

PLEASE NOTE: After you successfully submit your manuscript to the Editorial Office via the Editorial Management System, you will receive a confirmation email (!) to the email address specified in the sender’s profile. This letter confirms that the Editorial Office has received your manuscript. If you have not received the email, it means your manuscript submission is incomplete. Please return and finish it.

 

Mandatory Supporting Documents

Submissions should include a manuscript file and supplementary files:

  • Images, if any (upload each figure as a separate file);
  • A cover letter in a free format, signed by all the authors. Multiple identical letters containing all necessary signatures may be submitted (download the form).

If the authors need to add any files during the editorial process, the corresponding author who submitted the article to the Editorial Office should:

  • Log in to Editorial Management System on the journal’s website;
  • Open the Author section;
  • Click on the title of the corresponding manuscript;
  • Click the Summary tab (at the top of the page);
  • Use the Add a Supplementary File button to upload the file;
  • Enter the file title to describe the uploaded material.

Supplementary Files and Documents

To provide a comprehensive description of the article subject, the author may include supplementary materials, such as audio and video files, slide decks, tables of source data, or figures. The author must be the copyright holder for such materials and have not transferred these rights to anyone else, except for the publisher. Otherwise, the author must obtain written permission from the copyright holder to use the materials for publication and dissemination in our journal.

Supplementary materials are published online only. The publisher creates a permanent direct links from the article’s full text to any additional online files. The print version of the article will include a QR code and a link to each file, along with its name (e.g., “Supplement 1. Studies selected for meta-analysis. DOI: 10.17816/XXXXXX”).

Supplementary materials are often published in their original form, as submitted by the author. This is especially true for large, complex tables, audio and video files, and slide decks.

Supplementary materials are part of the article and are subject to all the guidelines and requirements set by the publisher, as well as current legislation and copyright laws applicable to independent copyrighted items. The terms of the author agreement signed at manuscript submission also apply to all supplementary materials.

 

II. General Requirements for Manuscripts


Manuscript Language

The journal only accepts manuscripts written in English. Citizens of Russia and the Commonwealth of Independent States may submit manuscripts in Russian.

Manuscript Master File

Accepted formats: *.doc, *.docx, or *.rtf. Files must be fully editable and unrestricted. Supplementary files and supporting documents may be uploaded in different formats.

Full Manuscript Length

  • Original studies, reviews and study protocols should not exceed 6000 words, including tables, figures, author information, and references. Systematic reviews, meta-analyses can be even bigger.
  • The full-text length of case reports or short communications should not exceed 4000 words.
  • Correspondence and other non-research works should fall within 1500 words.
  • The Editorial Office may consider manuscripts that exceed the word limit, but only with prior approval.

Manuscript Formatting

The manuscript, including text within tables and figures, should be typed in Times New Roman, 12 pt with 1.0 pt line spacing and 2 cm margins on all sides. Do not use hyphenation to break lines. For highlighting, use ONLY italics or bold, do not underline. Use the Find and Replace function to remove repeated spaces and extra line breaks. AVOID writing any text IN ALL CAPS, including your title, headings or subheadings.

Manuscript File completing

The file should include all information intended for publication, such as figures, tables, captions, and author information.

 

III. Manuscript Structure and Style Files


Types of Publications

  • Review
  • Systematic review
  • Meta-analysis
  • Original study
  • Brief communication
  • Study protocol
  • Case study
  • Correspondence

The journal may publish other types of original works (e.g., datasets, databases, technical reports, book reviews, commentaries and replies, consensus papers, discussions, lectures, biographies, news items, interviews, historical articles, or practical guidelines) and editorial communications (e.g., editorials, retractions, partial retractions, corrections, corrigenda, additions to previously published articles, or expressions of concern). These are not subject to the requirements below.

 

Style Files

The Editorial Office strongly recommends that authors adhere to the style file and recommendations therein. Each file briefly describes how to correctly present information in terms of sequence, format, and structure.

Please choose the Editorial Word template according to the type of your manuscript:

Article Structure

Please follow the international guidelines for transparent and accurate reporting data in scholarly articles at the EQUATOR Network platform (Enhancing the QUality And Transparency of health Research). The reporting guidelines for the main study types are:

Descriptions of statistical methods and results should comply with the SAMPL (Statistical Analyses and Methods in the Published Literature) guidelines.

 

IV. Referencing Guidelines

Any statement made by the authors must be supported by references to their opinions (“in our opinion,” “we believe,” etc.), personal experience (“unpublished data”), the opinions of others, or previous study results. The latter two must be supported by references to sources.

When a sentence or paragraph contains multiple statements, the references should be provided for each statement rather than placed at the end.

Each statement may be supported by references to no more than three (primary) sources. More sources should be justified, except for references in a systematic review.

References should prioritize primary sources, such as original studies, systematic reviews (if applicable), professional association guidelines, or consensus statements. Only if such sources are unavailable, the author may include references to opinions (including those in reviews), case studies, or scientific information sources that have not been peer-reviewed, such as preprints and press releases. The status of such sources should be explicitly indicated in the text.

Secondary sources (including reviews) should be used with caution; for example, when the original work is out of print, or unavailable through regular sources or in the original language. In this case, cite the original work in the text and add a reference to the secondary source to the reference list. Use the phrase “cited in/by...” to show that you have not read the original work.

Where applicable, specify the period covered by the source’s statements rather than the publication year. The latter may be irrelevant in the context of data interpretation.

Mention the names of the authors in the text (e.g., “[1st author’s last name] et al.”) only when such mentions provide essential context beyond the reported results. Otherwise, do not mention the names of authors in the text.

Place each source on a new line under its corresponding serial number in the reference list. For more information, see the Reference Formatting section. Below are the key requirements:

  • The list of primary sources should be arranged in the same order as they are cited throughout the text.
  • The number of cited works is unlimited; however, we recommend citing only the most relevant works.
  • In the text, cite your sources using Arabic numerals in square brackets (e.g., [1, 2]).
  • ALL AUTHORS must be listed in the bibliographic record for each source. For publications with more than four authors, use the abbreviation “... et al.” after the third author. Do not shorten the title of the article. Journal titles must be abbreviated according to the NLM Catalog (MEDLINE). If the journal is not indexed in MEDLINE, the full title must be provided. Do not abbreviate the titles of Russian journals.

The reference list should comply with AMA style (http://www.amamanualofstyle.com).

 

V. Use of Artificial Intelligence

The Editorial Office does not restrict authors from using artificial intelligence (AI) as a research tool. However, as with other research tools, authors must disclose their use of AI and specify the tool (software, platform, or service), version, developer, and source (URL, if applicable); the usage procedure; participants (researchers); queries (including their sequence and other relevant details); and time of use (if applicable). They must also verify the accuracy and reliability of the results obtained using AI and disclose the results of this verification. This description should be included in the Methods section or another appropriate section of the manuscript that describes the research methodology. The description of using AI for research purposes should be detailed enough to enable other researchers to replicate the approach.

The Editorial Office does not prohibit the use of AI for auxiliary purposes (e.g., improving text style and readability, or formatting the reference list). We strongly advise against using AI for translation purposes without having a professional translator verify the quality of the resulted translation. Information about using generative AI to write a draft manuscript, its parts, or other materials submitted to the Editorial Office must be disclosed in the Generative AI section of the manuscript (see the Additional Information section for text templates). This disclosure should specify the purpose and identify which parts of the manuscript or other materials were prepared using AI. It should also include the name of the AI tool (software or platform, indicating the URL), version, developer, and time of use, if applicable.

The authors must not list AI as an author or co-author, refer to AI as an author, or cite AI as an author (when using AI-generated texts or images).

 

VI. Manuscript Elements
Formulas

Mathematical formulas should be presented on separate lines using ONLY MathType (you may download MathType for Windows here).

PLEASE NOTE:

  • Do not use plug-ins or add-ons with similar names for office applications (e.g., MathType Add-In for Microsoft 365 or MathType Add-On for Google Workspace).
  • Do not use any built-in MS WORD tools (e.g., Equation Editor) to process formulas.
  • Do not use MathType to typeset notations with only a superscript or subscript, units of measure, numbers in text, or simple mathematical or chemical formulas
    (e.g., a2 + 2ab + b2 = (a + b)2; СH3СH2OH).
  • In formulas, use italics for Latin characters and upright font for Greek characters (MathType > Style > Define).

 

Statistical Analysis

The journal requires the use of appropriate statistical methods for publication. The statistical procedure must be described in the Methods section. A comprehensive list of all statistical methods and null hypothesis testing criteria must be provided. Accurate descriptions and applications of statistical analyses can substantially improve the reliability of the findings and their potential for use in future studies. Do not use vague statements such as “standard statistical methods were used.” Provide details about the applied methods, tests, and parameters. Avoid common misconceptions about p-values, such as the “probability of the null hypothesis,” the “probability that the observed difference is due to chance,” or the “probability of rejecting the null hypothesis.”

We recommend that authors collaborate with professional statisticians for studies involving more than two paired comparisons. Specify the level of significance (p-value) used in this study (e.g., “The critical level of significance used to test statistical hypotheses in this study was p < 0.005”). The exact p-value for each statistical test should be provided, such as “p = 0.015” or “p = 0.267,” rather than “p < 0.05” or “p > 0.05.”

The exact values of the statistical tests should be specified (e.g., the Pearson chi-squared test is χ2 = 12.3 (df = 2, p = 0.0001). Avoid the vague use of terms with multiple meanings. For example, there are several types of correlation coefficients: Pearson coefficient, Spearman coefficient, etc.

All statistical terms, abbreviations, and symbols must be defined (e.g., M, mean; m, standard error of the mean; SD, standard deviation; p, significance level).

If the statistical tests and parameters are limited in use, explain how these limitations were tested and what the results were. For example, for parametric methods, specify which normality test was used for the sample distribution (e.g., Kolmogorov–Smirnov, Shapiro–Wilk, Anderson–Darling, or D’Agostino–Pearson tests). Define all symbols and include the sample size (n) for expressions such as M ± m.

Note that parameters M ± m and M ± SD can only be used to describe the quantitative characteristics of a group when the data are normally distributed.

Use a parametric Student’s t-test only after testing for equality of variances. If they are not equal, use the Welch’s t-test instead. For an analysis of variance, specify which test was used to check for equality of variances: Fisher’s exact test, Cochran’s Q test, Bartlett’s test, Levene’s test, or Dunn’s test.

When three or more groups are being compared, specify the procedure used to adjust for multiple comparisons.

For risk assessment, clearly distinguish between odds ratios, risk ratios, relative risks, and absolute risks.

Specify the name of the statistical package used for data analysis, e.g., BMDP, STATGRAPHICS, MINITAB, MEDCALC, SYSSTAT, STATISTICA, SPSS, R, CSS, STADIA, EVRISTA, SANI, BIOSTAT, MESOSAUR, DATASCOPE, STATA, SAS, EPIINFO, SOFA, MS EXCEL, S-PLUS, MSL-C, STAT-MEDIA, NCSS, JMP, etc. Please also indicate the version number (e.g., SYSSTAT 5.0.6), developer, and country.

Example: STATISTICA v.13 (StatSoft, USA) was used for data analysis.

For more details on the requirements for statistical presentation, see the SAMPL (Statistical Analyses and Methods in the Published Literature) guidelines.

 

Taxonomic Nomenclature

The manuscript must use the generally accepted name for a study object, as established by taxonomic nomenclature. Latin genus and species names should be italicized (e.g., Homo sapiens), whereas higher-rank taxa should be set in upright font (e.g., Vertebrata or Metazoa). At the first mention, a genus or species name should be spelled out in full (e.g., Escherichia coli). Subsequent references should abbreviate the genus name, but not the species name (e.g., E. coli).

Taxonomic authorities should only be cited once: either when a taxon is first mentioned in the text or in designated lists if applicable. Do not italicize Syntaxon names.

Latin animal names must adhere to the International Code of Zoological Nomenclature (ICZN). Plant names and authorities must follow the standards adopted by the International Plant Names Index (IPNI) or The Plant List. Herbarium acronyms should follow Index Herbariorum.

The nomenclature for genetic variants varies by organism. Please verify the correct notation in the appropriate databases.

 

Genetic Nomenclature

Authors must verify gene and product names in relevant databases and use current, standardized symbols because genetic nomenclature varies among species. For gene and product names, see here and here.

Avoid using terms such as polymorphism or mutation for reference nucleotide variants differing from the reference nucleotide sequence. Use neutral terminology instead, such as variant or substitution (single nucleotide variant, SNV).

The first time a gene is mentioned in the text (outside the abstract), a footnote describing the gene in the relevant database should be included. Example: HLA-DRB1 [1].

Use italics for gene symbols, genotypes, messenger ribonucleic acid (mRNA), complementary DNA (cDNA), and mobile genetic elements. Do not italicize full gene names, protein products, and phenotype descriptions. Do not use Greek letters, Roman numerals, dashes, hyphens, superscripts, or subscripts for the gene symbol, unless they are being used to designate a gene product or phenotype.

 

Example:

Gene

Poly(ADP-Ribose) Polymerase 1

Gene symbol

PARP1

Protein

PARP1

Genotype

PARP1+/-

Phenotype

PARP1+

mRNA

mRNA PARP1

cDNA

cDNA PARP1

Mobile element

TY

 

Gene symbols may be written in uppercase or lowercase, depending on species-specific nomenclature rules.

 

Example:

Species

Gene (symbol)

Protein

Escherichia coli

rdgB

RdgB

Saccharomyces cerevisiae

ADE2

Ade2

Homo sapiens

POLD1

Pol δ

Mus musculus

Tnfa

TNF-α

 

Human genomic variants should be described in accordance with the Human Genome Variation Society (HGVS) nomenclature.

 

Example:

Gene

Tumor protein p53

Symbol

TP53

Gene Nomenclature Committee ID

HGNC:11998

Genotype variants

 

Position of cDNA substitution

TP53: c.488A>G

Genomic position (including the reference sequence)

TP53: g.7578442T>C (GRCh37.p13 chr 17 NC_000017.10)

Position of protein substitution

p.Tyr163Cys

Cis-heterozygosity

g.[7578442T>C;7577129A>C]

Trans-heterozygosity

g.[7578442T>C];[7577129A>C]

Heterozygote with unknown allelic configuration

g.[7578442T>C](;)[7577129A>C]

 

The nomenclature for genetic variants varies by organism. Please verify the correct notation in the corresponding databases.

The first time a gene is mentioned in the text (outside the abstract), a footnote describing the gene in the relevant database should be included.

Example: HLA-DRB1 (https://omim.org/entry/142857?search=HLA-DRB1&highlight=hla).

 

Abbreviations

All abbreviations and symbols, including those in common use, should be defined at first mention in the text. Do not abbreviate terms in article titles, abstracts, section headings, tables, or figure captions.

 

Tables

Place tables in the Tables section at the end of the article. Each table should have a numbered header and clearly marked columns to make it easier to read. The table data must align with the text. However, publication rules prohibit duplicating table data in the manuscript text. Each table must be referenced by a number in the article text.

All tables in the article must be numbered consecutively. A single table should also be numbered. Avoid abbreviations (except for commonly used ones) in the table header.

We recommend moving tables with more than four columns and a height exceeding one page to a Supplement. In this case, the text should reference the Supplement and not the table.

Any explanations of abbreviations and symbols used in the table should be placed in the Note below the table. For tables and their descriptions, make sure the main content is clear and does not require referencing to the manuscript text.

 

Example of a table header:

Table 2. Clinical and pathological characteristics of patients

How to reference it in the text:

Table 2 shows the clinical and pathological characteristics of the patients.

 

Figures

A figure (image) is a visual representation of an object (diagram, drawing, picture, photo, map, etc.), numerical values (line, plane, or geometric figures), formulas (nomogram), processes, or phenomena (graph, flow charts).

Graphs and diagrams should be created using vector graphics editors, such as Adobe Illustrator, Corel Draw, or text editors (e.g., MS Word, MS Excel, MS PowerPoint). For vector graphics, all used fonts must be embedded in the file. To do this, select the Embed Fonts option when saving the file.

Figures should not have any gray (colored) background or grid. Please pay special attention to the colors used in figures, including those in simple line charts (see more information here).

Only image files (!) uploaded as supplementary materials via the Editorial Management System will be used for publication.

 

Figure Location

Place each figure on a separate page at the end of the manuscript file.

All figures must be cited in the text in parentheses using the abbreviation “Fig.” followed by the figure number.

Example: (Fig. 1).

 

Images within multi-panel figures should be denoted by lowercase Latin letters in the text.

Example: (Fig. 2b).

 

All graphs, diagrams, charts, drawings, and other figures created using MS Office or other text editors, as well as all photos (including screenshots), must be high-contrast and clear. The number of figures should be kept to a minimum unless it is necessary for the type of your work.

Example:      

Fig. 1. Study protocol.

 

Photos, screenshots, and other raster (NON-vector) images must also be uploaded separately in the designated section of the submission form. Accepted formats include *.tiff, *.eps, *.jpeg, *.bmp, and *.gif. Use *.doc or *.docx for annotated images only. Use Calibri font for all text within figures. The image resolution must be >300 dpi. Vector images should be submitted in files with the following extensions: *.ai, *.eps, or *.cdr. Each file name must contain the figure number in the manuscript. Each uploaded file should be accompanied by a caption identical to the figure title used in the text. 

Example:

Fig. 1. Ivan Sechenov.

 

Caption

Each figure should have a caption that includes the following: 1) the symbol and serial number; 2) title; 3) legend; 4) note; and 5) information about a copyrighted item. Explanations for points 3–5 should be provided as required.

1) Figure designation and numbering. All illustrations must be designated as figures. All figures must be numbered, even if only one is provided. Figures must be numbered consecutively throughout the manuscript (e.g., 1, 2, 3).

2) Figure titles should be concise and descriptive. For multi-panel figures, the main title should include designations for each image. For more details, see the Legend section. Avoid abbreviations in figure titles (even those defined in the main text). Alternatively, define them in the figure legend.

3) A legend explains symbols (such as letters, numbers, and graphic signs) or unmarked details in a figure.

  • Use Latin letters to label multi-panel figures, and digital or graphic indicators for figure elements.
  • All symbols in the figure should be explained after the main title. First, explain the symbols in images of a multi-panel figure. Then, explain the symbols within the figure elements.
  • For a multi-panel figure with separate numbering for each image, first explain the details of the first image, then the details of the second one, and so on.
  • For any unlabeled elements, explain then below the legend.

4) Note. A note is used to clarify a figure title and legend.

  • A note is required to make the image understandable without referring to the main text. This part of the caption should include measurement methods, imaging techniques and scale, and other details for evaluating the figure as a whole without reference to the main text.
  • The note must end with a definition of all abbreviations used in the title, legend, or image.
  • Do not use the Note term in the caption!

5) Information about a copyrighted item. The manuscript may present original images (created and owned by the authors, previously unpublished elsewhere) and third-party images (from previously published or unpublished sources).

 

PLEASE NOTE: Images from unknown sources (including those intentionally anonymized) are not accepted for publication.

  • Captions for original images should not include information about the authors or copyright holders. If the work is published, this information will appear on the title page of the article and will apply to all content, including the original images. Figure captions should end with a title and, where applicable, a legend or note.
  • For third-party images, information about a copyright holder and authors should be included in the caption.
    • For previously published third-party images (including those previously published by the same authors) or previously unpublished third-party original images (e.g., from institutional, family, or personal archives), three statements must be included in the figure caption: 1) a copyright statement; 2) terms of use for the copyrighted item; and 3) a summary of any modifications made to the original image.
    • Always (!) specify sources for third-party images.
    • The copyright statement must include: the copyright symbol (©); the name of the copyright holder (for a group of individuals (co-authors), use the first author’s surname followed by “et al.”; for legal entities, use the short official name of the organization (omitting the legal form and departmental affiliation); if the holder’s identity is withheld for legal reasons, specify the source (e.g., “family/personal archive of the patient or their legal representative”); the year of publication.
    • Specify the terms of use for an original image as stipulated by the copyright holder:
      • Use the statement “Reproduced with the copyright holder’s permission” if:
        • The copyright holder (including a patient or their legal representative) retains all rights to previously published or unpublished third-party images. The authors of the manuscript must obtain permission from the copyright holder to publish the image in any media (including electronic versions) and to translate or modify the text elements, if any;
        • A third-party image is used under conditions that are different from those specified in the open license. In this case, the manuscript authors must obtain permission from the copyright holder to use the image under the new conditions.
      • Use the statement “Distributed under the license CC…” if a previously published or unpublished third-party image is used under the conditions of an open license (e.g., CC-BY).
    • At the end of this part of the caption:
      • For a third-party image used as is, use the statement “Source: Reproduced from...” and provide a numbered reference to the image source (“...[reference]”) or a URL if the figure is posted online.
      • If you use a third-party image with translated text elements, use the statement “Source: Adapted from [reference] (or URL).” For original images with substantial modifications, use the statement: “Source: Reproduced/Adapted with modifications from [reference] (or URL).” This includes patient photographs obtained from the patient or his/her legal representatives where certain details have been obscured by the authors.
      • For previously unpublished third-party images, use the statement “Source: Personal/family archive,” “Archive of [Institution],” or “Archive of [Department of Institution].”

 Examples:

  • Fig. Х. Title. Figure caption... From the family archive of the patient, previously unpublished. Reproduced with permission from the parent.
  • Fig. Х. Title. Figure caption... From the archive of [Organization], previously unpublished. Reproduced with permission from the administration of the institution.
  • Fig. Х. Title. Figure caption… The chart is reproduced from [reference]. © 2022 BMJ Publishing Group Ltd. All rights reserved.
  • Fig. Х. Title. Figure caption… The nomogram is adapted from [reference]. © 2022 BMJ Publishing Group Limited. Distributed under the license CC-BY.
  • Fig. Х. Title. Figure caption… The figure is adapted from [reference]. © 2014 Ivanov et al. Distributed under the license CC BY-ND-SA 4.0.

 

Ethics Compliance Information

The publisher and the Editorial Office adhere to strict publication ethics standards and do not permit the publication of works that directly or indirectly violate these principles.

Authors should include relevant information in their manuscripts to assure the editorial staff and readers that their work adheres to all applicable international publication ethics standards (and biomedical ethics standards for biology and medical journals).

Much of the information confirming ethical compliance may be included in the Additional Information section (please refer to the article template for formatting guidelines). Below is the structure of this section, with explanations provided for each section.

The Publisher’s Code of Ethics and the publication ethics standards followed by the editorial staff may be found on the respective pages:

 

Additional Information

The Additional Information section of the manuscript (see editorial templates) asks authors to provide information that may influence the opinions and decisions of editors, readers, researchers, and other stakeholders. Present the required information as brief statements that contain the most relevant details. Authors must provide information for every item in this section. The Acknowledgments, Consent for publication, and Disclaimer statements should only be added if applicable.

 

PLEASE NOTE: The journal reserves the right to discontinue the review process or retract the published article if the authors are found to have intentionally submitted inaccurate information. The editorial staff and the publisher may terminate the editorial process without prior consultation with the Editorial Board and editor-in-chief. In case of retraction of a published article, an editorial investigation is initiated. Based on such investigation, the editor-in-chief decides whether the article should be retracted. The editorial staff reserves the right to notify any institutions mentioned in the manuscript about any major violations of research or publication ethics. For more details, see the Editorial Policy.

 

Author Statements
1) Author contributions

A research is a complex activity that usually involves multiple parties with different roles and levels of involvement in the research process. The roles of researchers must be clearly defined so that their contributions can be evaluated fairly, their responsibilities be determined, and disputes over authorship or unfair publishing practices be prevented.

  • Please use the CRediT system (see here) to describe the contributions of each author, as listed on the title page of the manuscript.
  • Typical role description: First author’s full name: role(s) (one or more roles using the CRediT system); second author’s full name: role(s); etc. OR: Use a role as a grouping factor and put the names of corresponding authors after a colon. This is preferable for studies with multiple authors. Please consult the journal’s editor on using this option.
  • Manuscripts with a single author should also have the Author contributions section.
  • Always finalize your Author contributions section as follows: The author [or All the authors] approved the version of the manuscript to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

 

Examples

Author contributions: John M. Doe: conceptualization, investigation, data curation, writing—original draft, writing—review & editing; Disha Srivastava: data curation, writing—review & editing; Juliette James: data curation, investigation, writing—review & editing; Jane Doe: data curation, writing—original draft, writing—review & editing. All the authors approved the version of the manuscript to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Author contributions: Conceptualization: John M. Doe, Juliette James; investigation, data curation, writing—original draft, writing—review & editing: Juliette James, Disha Srivastava. All the authors approved the version of the manuscript to be published and agreed to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Author contributions: John M. Doe: conceptualization, investigation, writing—original draft, writing—review & editing.

 

2) Acknowledgments

Assistance in the investigation and dissemination of results is insufficient for the recognition of authorship (more information on the authorship criteria here). However, acknowledgment of assistance is an important aspect of academic integrity. By acknowledging other study contributors, you demonstrate respect for their efforts. This approach fosters sustainable professional relationships, accurately defines your contribution, and ultimately strengthens public trust in you and your work. Acknowledgements may not be made to anonymous individuals or institutions (some exclusions are possible).

Key considerations:

  • Non-author contributions must be specified, preferably using the CRediT system (https://credit.niso.org/), but may be presented in free form.
  • The authors must ensure that the acknowledged individuals have agreed to be mentioned. Specify that the individuals mentioned do not object to being acknowledged at the end of this paragraph. This information is not published. For a group of individuals, be sure to receive the consent from their representative.
  • Acknowledging professional writing support in manuscript preparation, review, and editing is mandatory. Consent from professional writers is not required.
  • If you have no one to express your gratitude, please specify “Not applicable.” In that case, this statement will be removed from the article upon publication.

 

Examples

Acknowledgments: The authors express their gratitude to faculty members and employees… [the short official name of the organization (country)], specifically Associate Professor… [initials and surname] for histological analysis, and Junior Research Associate... [initials and surname] for statistical analysis, and to Professor [initials and surname] (the short official name of the organization, country) for critical review and assistance in manuscript preparation.

[Initials and surname], [initials and surname], and [initials and surname] do not object to being mentioned by name. [This part will not be published.]

 

3) Ethics approval

The study authors have ethical obligations to society arising from their use of public resources (financial and non-financial), potential social consequences of their work, the high risk of violating the rights and interests of study participants, inhumane treatment of animals, and mitigation of the potentially negative environmental impact of their study. Given that ethical obligations vary on a case-by-case basis, please describe the actions you took to comply with the generally accepted standards of academic ethics and explain any deviations from these standards.

  • Report the following:
    • 1) The result of the study protocol approval by an ethics committee or another competent authority with similar functions received prior to the study;
    • 2) Obtaining an informed consent to participate in the study, as well as to use the materials and/or data from participants (more details here and here);
    • 3) Registration of the study (and its protocol).
  • Any refusal to perform the specified actions must be documented. If no ethics approval statement or informed consent have been obtained, the reasons must be explained.
  • If you have an ethics approval statement, please provide information about the committee’s opinion (e.g., “the study protocol was approved,” “the request for ethics approval was rejected,”). Specify the type of ethics committee (e.g., independent, local, or other expert authority), its affiliation, the minutes number and the date of signing. The editorial staff may request an electronic copy of the statement, as well as the contact information of the representative of the ethics committee.
  • When obtaining informed consent, please specify whether the consent is written or verbal; the purpose, such as the use and/or dissemination of materials for research purposes, study participation, etc.
  • For a registered study, specify the place of registration (platform, database, journal, preprint repository, etc.), registration message identifier (URL, digital identifier, bibliographic record, etc.), and initial publication date of the message.

 

Authors may seek further clarification from the local ethics committee at their employing organization or from an independent ethics committee that reviews study protocols involving human participants, including studies using human materials and data.

 

PLEASE NOTE:

  1. Authors cannot exempt themselves or their study from having their study protocol reviewed by the ethics committee before the study initiation. Only an ethics committee may decide whether an ethical approval is required.
  2. The requirement for ethical approval is independent of the study design. Medical research protocols involving human participants, including studies of [identifiable (per the Declaration of Helsinki, 2024) or non-identifiable (per the WHO-endorsed CIOMS International Ethical Guidelines for Health-related Research Involving Humans, 2016)] human materials and data, must be approved by an ethics committee. The status of materials and data as “non-identifiable” (which is not equivalent to “anonymized”) must also be confirmed by an ethics committee.
     — Declaration of Helsinki, Paragraph 1: The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human participants, including research using identifiable human material and data. ...23. The protocol must be submitted for consideration, comment, guidance, and approval to the concerned research ethics committee before the research begins.
     — CIOMS Guideline 12: “The protocol for every study using collected data must be submitted to a research ethics committee…”
  3. According to Paragraph 36 of the Declaration of Helsinki:

“...Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.”

Please note that since 2002, the Russian Professional Medical Association (known as the National Medical Chamber since 2018) has been a collective member of the World Medical Association, whose General Assembly adopts updates to the Declaration (the most recent being in 2024).

 

Examples

Ethics approval: The study protocol was not reviewed by an ethics committee. No informed consent for participation in the study was obtained. Reason: the study used public data, which does not contain any personally identifiable information about patients. The study was registered at [name of the institution with the URL for study registration message] on [initial publication date of the message in Month dd, yyyy format].

Ethics approval: The Independent Ethics Committee of [official name of the institution where the committee operates] rejected the request for an expert review of the study protocol (Minutes No. ... dated [Month dd, yyyy]). Reason: [excerpt from the statement]. All participants provided written informed consent. The study and the its protocol were not registered.

Ethics approval: The study was approved by the Independent Ethics Committee of [official name of the institution where the committee operates] (Minutes No. ... dated [Month dd, yyyy]). All participants provided written informed consent to participate in the study including the use of study data. The study protocol is available at [URL of the protocol], published on [Month dd, yyyy].

Ethics approval: The study was approved by the Local Ethics Committee of [official name of the institution where the committee operates] (Minutes No. ... dated [Month dd, yyyy]). All participants provided written informed consent for the use of their clinical assessment and treatment data for research purposes on admission. The study protocol was published in the [journal reference]. The manuscript was submitted on... [Month dd, yyyy].

 

 

4) Consent for publication

Each manuscript that contains confidential information of an individual (personal data, photographs, protected health information, or any other facts, events, and circumstances of the individual’s personal or professional life), must include a statement on obtaining their informed consent for publication (!) of these data in a journal, including its online version. Personal data of children (individuals aged 0–17 years) can only be published with the permission of their legal representative.

Publication of confidential data of an individual after their death also requires consent of legal representatives. One exception (determined by the importance of provided information) is when legal representatives or immediate family members cannot be located despite reasonable efforts of the authors. In such cases, describe the actions taken to locate legal representatives or immediate family members of the deceased individual.

In cases where informed consent for publication of confidential data was not obtained, specify the reason. This information is published.

In the Ethics Approval section, specify whether informed consent for participation in the study (!) and/or the use of materials and data for research purposes was obtained from participants.

If you have obtained informed consent for publication, please provide the following information:

  • Consent form (verbal or written), signer (patient, legal representative, or other person), and signing date.
  • The authors must confirm that the scope of published confidential data has been agreed upon with the patient and/or their legal representative. This information is published. Insignificant personal information must be removed from the manuscript, even if the authors have obtained informed consent for publication of confidential data.

 

Examples

Consent for publication: Written informed consent was obtained from the patients [and/or their legal representatives] for the publication of their confidential data, including photographs [with faces obscured], in a scientific journal and its online version (signed on December 25, 2023). The scope of the published data was approved by the patient [and/or their legal representative].

Consent for publication: No informed consent was obtained from the patient for publication of information on their health status during hospitalization. Reason: the patient was lost to follow-up (the telephone number specified in the medical record was blocked; the e-mail address was unknown; and contact information of the patient’s family members was unavailable). All data presented are anonymized, and no photographs are published.

 

5) Funding sources

The mandatory declaration of funding sources, including the preparation and publication of results reports, is important for several reasons: to inform readers about sponsors, maintain records necessary for controlling the expenditure of allocated research funds, and analyze the effectiveness of funding institutions for science in general and specific research programs. Funding sources may include for-profit or not-for-profit organizations, individuals or groups of individuals, state funds, and the author’s affiliated institution (internal targeted funding, excluding salaries and costs of research covered under standard job duties).

Provide the following information:

  • Please disclose the sources of funding for your research (!), regardless of time when the relevant support was provided. If the funding source is an institution, please specify its country of residence.
  • If funded, please indicate the form of support provided (options: direct (monetary) funding, indirect support, including the provision of tangible assets [consumables such as drug products, reagents, commercial kits, etc.]; fixed assets [equipment, software, etc.]; intangible assets [intellectual property, permits, etc.]; or services [logistics, consulting, training, and other third-party services]; laboratory animals, cell lines, etc.). A digital or another permanent identifier is typically specified for grants or contracts.
  • Describe the role of the funding source (options: conceptualization and design; control of inclusion criteria; enrollment; evaluation of study endpoints and registration of outcomes; data collection and verification; data analysis, interpretation, and management; data storage; formation of study team, management or other structures for study monitoring, oversight, and auditing; study management; logistics support; manuscript preparation, revision, and editing; manuscript approval; decision to submit the manuscript for publication; other [specify]). Specify if the source you mention was not involved in the study organization, planning, execution, or supervision; data collection, storage, analysis, or interpretation; manuscript preparation, making the decision to submit it for publication.
  • Disclose any restrictions that the funding source has imposed on data utilization or the dissemination of study findings, or absence thereof.
  • If the study had no funding sources, specify “No funding.”

 

Examples

Funding sources: No funding.

Funding sources: The study was funded by [name of the funding organization] (country) (Grant No. …); reagents were provided by [name of the organization] (country). The company was not involved in the study organization, planning, execution, or supervision; data collection, storage, analysis, or interpretation; manuscript preparation, making the decision to submit it for publication. The funding organizations imposed no restrictions on data utilization or the dissemination of study findings.

Funding sources: This review was prepared and published (with a submission fee) using funds from a research grant received from [name of the institution] (country). [The institution] was not involved in the study organization, planning, execution, or supervision; data collection, storage, analysis, or interpretation; manuscript preparation, making the decision to submit it for publication. The authors have full access to all search and review findings.

 

6) Disclosure of interests

Any funding of the submitted research work (direct or indirect research funding, including publication of the results) must be specified in the Funding Sources section.

In the Disclosure of Interests section, the authors declare that they have or have no relationships with any stakeholders (for-profit or not-for-profit third parties, physical individuals) whose interests may be affected by the content of the article. To maintain transparency and trust in the research process:

  • Declare that you have or have no relationships, activities, or interests for the last three years, specifying the stakeholder and form of relationships, activities, or interests;
  • Possible options:
    • Primarily financial (grants or contracts from any institution; author’s fees or licenses; consulting fees; honoraria for lectures, presentations, public speaking arrangements; manuscript preparation or educational events; expert speaking fees; participation in meetings or travel expenses [business trips, etc.]; planned, issued, or pending patents; stocks or stock options; gifts), including resource allocation (equipment, materials, drug products, medical publications, other services);
    • Primarily non-financial (participation in unpaid activities on behalf of third parties; personal or professional interest in a particular activity or in obtaining a specific result; political or religious preferences; other).
  • Disclose not only direct relationships with third parties (e.g., receiving funds for purposes unrelated to this study), but also relationships through your affiliated institution.

The authors may use the Uniform Format for Disclosure of Competing Interests in ICMJE Journals by the International Committee of Medical Journal Editors (ICMJE).

 

Examples

Disclosure of interests: The authors have no relationships, activities, or interests for the last three years related to for-profit or not-for-profit third parties whose interests may be affected by the content of the article.

Disclosure of interests: Initials and surname [one of the authors]: research grant from [name of the institution] (country), education and consulting fees from [name of the institution] (country); initials and surname [one of the authors]: conference management for [name of the institution] (country). Other authors have no relationships, activities, or interests for the last three years related to third parties whose interests may be affected by the content of the article.

 

7) Statement of originality

The failure to disclose the reuse of previously obtained (collected or created for a purpose other than that of the present work) and published first- or third-party information (data, code, text, tables, and images residing on physical or electronic media, on the Internet, and potentially accessible to an unlimited number of persons) constitutes an unacceptable research practice.

  • To avoid suspicion of research misconduct, please disclose any reuse of previously obtained and published information in the article, or emphasize the originality of the current work (e.g., using data collected or created for the first time).
  • When using previously obtained or published material, specify the scope (in full or in part), authorship (first-party or third-party), format (text, images, or data), authorship and source (with a citation of the latter; for data citation, see here), and copyright holder’s terms of use and distribution (copyright permission, license agreement, public domain, or other).

 

Examples

Statement of originality: No previously obtained or published material (text, images, or data) was used in this study or article.

Statement of originality: This article contains extracts from our previously published work ([bibliographic record or DOI], distributed under the license CC-BY 4.0).

Statement of originality: This work used first-party data for the control group (in full), an MRI image (Fig. 2) that was used in our previously published work ([bibliographic record or DOI], distributed with the copyright holder’s permission). Additionally, the Background section used text from [specify initials and surname] PhD thesis.

Statement of originality: This work used an image (pathogenesis of the disease, Fig. 1) adopted from... [Surname] et al. [reference] (distributed under the license CC-BY 4.0).

 

8) Data availability statement

Data refers to any information used (third-party data) or obtained (collected or created) in a study. The authors must report the use of previously published first- or third-party data in the Methods section or other section appropriate for describing the research methodology, as well as in the Statement of originality section. Specify whether the article and/or its supplements present all the data obtained in the study (typical for review papers and case reports). In such cases, the editorial policy of the journal regulates data availability (access to the full text of the article and supplements).

If the article or its supplements do not present any dataset including images, text, code, etc., the following options are possible:

  • Data not available: This statement must be justified, indicating why the data are not available: due to confidentiality, safety issues, ethical, legal, and/or commercial limitations of data sharing.
  • Data subject to restrictions: The reasons and nature of restrictions must be specified (on request, embargo, other [specify]). If the on-request restriction is used, the following must be specified: the form of request (free-form rationale or a request that includes, for example, the planned study protocol, ethics committee approval, statistical analysis plan, signed data use agreement, etc.), contact person (author or representative of the sponsor or another copyright holder), and scope of data that will be made available. If the embargo restriction is lifted, the time until the embargo is lifted must be specified.
  • Data openly available in a public repository: In this case, provide access details, including the data location or source name (e.g., repository or other), the link (or bibliographic reference, URL, or persistent digital identifier of the data location), and the terms of data distribution (e.g., type of open license).

Access to data from human studies (open or limited, full or partial), including studies of human biological materials and data, requires the permission of individuals (except for anonymized data, which cannot be identified even with additional information) and their legal representatives (in some cases, including after the participant’s death), and ethics committee approval. The authors must report compliance with this condition in the Ethics Approval section.

For more information on data citation (whether previously published first- or third-party data or generated or collected in the present study), see here.

 

Examples

Data availability statement: All data obtained in this study are available in the article.

Data availability statement: All data obtained in this study are available in the article and its supplementary material. In particular, Supplement 1…

Data availability statement: The data obtained in this study cannot be made publicly available for confidentiality reasons (the database contains personally identifiable information of study participants, and the participants did not consent to dissemination of this information or private health information).

Data availability statement: The data obtained in this study cannot be made publicly available subject to a contract with the copyright holder (study sponsor) [name, country]. By agreement with the copyright holder, the study data will be available 12 months after publication of this article upon reasonable request (a brief description of the planned study protocol is mandatory).

 

9) Generative AI

Artificial intelligence (AI) is a set of technological solutions that imitate human cognitive functions. This set includes information and communication infrastructure, software (including those that use machine learning methods), and processes and services for data processing and search for solutions. AI technologies encompass computer vision, natural language processing, speech recognition and synthesis, and intelligent decision support. The authors must describe any use of AI for research purposes (study planning and conduct, data collection and analysis, statistical analysis) in the Methods section.

This section must contain the following:

  • The authors must specify whether they used generative AI to prepare the manuscript, its parts (including images), or other submitted materials;
  • If AI is used for these purposes, the authors must specify the technology (or large language models, chatbots), purpose of use (to prepare the manuscript, its parts [specify], images, etc.), tool (software, platform, or service, indicating the URL as applicable), version, developer (country), and time of use (up to the month).

 

PLEASE NOTE: The authors must not list AI as an author or co-author, refer to AI as an author, or cite AI as an author (when using AI-generated texts or images. For more information on the journal’s editorial policy regarding the use of AI, see here.

 

Examples

Generative AI: No generative artificial intelligence technologies were used to prepare this article.

Generative AI: This article [or article (in full or in part), author’s abstract, images, tables, etc.] was prepared using [tool], version [version number] (developer, https://...). The chatbot was used from March to April 2024.

 

10) Provenance and peer-review

Articles published in the journal may be submitted unsolicited or commissioned by the journal; be reviewed following the fast-track or standard procedure; and be peer-reviewed by independent experts and other stakeholders, including those associated with the Editorial Office. To ensure transparency and properly inform readers, please disclose the origin of the manuscript upon submission (whether it is an unsolicited submission or was commissioned by the editors/editorial board).

 

Examples

Provenance and peer-review: This article was submitted unsolicited.

Provenance and peer-review: This article was commissioned by the Editorial Office.

 

11) Disclaimer

A disclaimer may be issued by the authors or their affiliated or otherwise associated institutions regarding any potential consequences arising from the publication of the article. This section will only be published at the authors’ request.

 

Examples

Disclaimer. The authors declare that the views expressed in this article are solely their own and do not necessarily reflect the official positions of their affiliated institutions [or the study sponsor, or any other stakeholder].

Disclaimer. The information presented in this article is intended for professionals only. The results and conclusions of this case study should not be considered as clinical guidelines. The authors are not liable for any misuse or application of the information contained herein.

 

 

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with each of the following items, and submissions that do not adhere to these guidelines may be returned to the authors.

    • Absence of plagiarism

    The authors guarantee that this article has not been published in whole or in part, and is not under consideration or in the process of publication in another publication.

    • Correct manuscript format

    Manuscript file format is Microsoft Word (has the extension *.doc, *.docx, *.rtf). The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

    • Anonymity

    All information allowing to identify authors is removed from the text of the manuscript and from the metadata of the file

    • Structure

    Abstract is designed in accordance with the requirements and do not exceed the limit

    • Illustrations

    Tables and figures were placed within the text of the manuscript and have their titles.

    • Bibliography

    The list of references is formatted in accordance with the requirements. All the cited sources were checked for DOI.

    • Supplementary files

    The authors have prepared for transfer to the editor:

      • file containing full information about the authors (Surname, first name, place of work, e-mail address);
      • graphic files (photos, satellite images, graphics, etc.).
      • the authors are ready to upload these files to the journal website in Step 4 during the manuscript submission process.
    • Authorship

    The authors confirm that:

      • all participants who have made a significant contribution to the study are presented as co-Authors;
      • those who did not participate in the study are not listed as co-Authors;
      • all co-Authors have seen and approved the final version of the work and agreed to submit it for publication
 

Copyright Notice

Authors who publish with this journal agree to the following terms:

  1. Authors transfer article copyright to the publisher only after the acceptance to publication.
  2. Authors are able to use and distribute the article in accordance with Self-Archiving policy of the journal (see details).
  3. The article can be accepted for publication only by decision of the Editor-in-Chief and the Editorial board of the journal in accordance with the Manuscript stelection policy of the journal (see details).
  4. Published Article will be distributed in print and electronic version an will be available under subscription with Delayed Open Access or in Immediate Open Access under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The access model depends on the publisher's decision or is determined by a separate Open Access publishing agreement with the authors.

 

Other copyrights not directly transferred to the publisher under the License Agreement, including patent rights to any process, method etc., described by the Authors in the article, as well as trademark rights, are reserved for the Authors.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Medical academic journal'.

 

READ the details online (tap to see in details)

 

Copyright transfer agreement for publishing a scientific work in a scientific journal (public offer)

ver. 18.11.2025

LLC "Eco-Vector", represented by its CEO Evgeniy Schepin acting on the basis of the Charter (“Publisher”), on the one part, offers an indefinite number of persons (“Author”), on the other part, hereinafter jointly referred to as the Parties, to execute this agreement (“Agreement”) on the transfer of the exclusive right to the intellectual property – the scientific article and its publication in the Publisher’s journal under the following conditions.

 

I. General Provisions

  1. This Agreement, in accordance with clause 2 of Article 437 of the Civil Code of the Russian Federation, is a public offer (“Offer”), full and unconditional acceptance of which, in accordance with Article 438 of the Civil Code of the Russian Federation, means the sending by the Author of his/her materials by uploading the same to the online electronic manuscript submission system, placed in the corresponding section of the Journal’s website on the Internet information and telecommunications network (“Internet”).

 

II. Terms used in the Agreement

  1. “Author” refers to an individual (or individuals) whose creative work has led to the creation of the manuscript of a scientific Article, or to an authorized representative of these persons.
  2. “Manuscript” is the result of intellectual activity in the form of a scientific work containing text, graphic and numerical data, audiovisual information, program code and other elements submitted by the Author for publication in the Journal.
  3. “Acceptance of the offer” refers to the full and unconditional acceptance of the offer on the terms specified in paragraph 3 of this agreement (the Author accepts offer by submitting a Manuscript to the Publisher via the online electronic manuscript submission system on the Journal’s Internet website).
  4. “Journal” is a scientific peer-reviewed periodical (and/or online media) registered as a mass media entity in the register of Federal Service for Supervision of Communications, Information Technology, and Mass Media (Roskomnadzor).
  5. “Submission” is an electronic application of the Author to the Publisher for the publication of an Article Manuscript in the Journal by uploading the manuscript, additional files and accompanying materials to the online electronic manuscript submission system on the Journal’s Internet website).
  6. “Publisher” refers to Eco-Vector LLC.
  7. Article metadata includes the information on the Article Manuscript and/or Article that are intended for inclusion in International Scientific Databases, namely the following:
    • Title of the Article;
    • Information about each of the Authors (surname and first name, patronymic; place of work with the postal address indicated, contact information (e-mail));
    • Abstract;
    • Keywords;
    • Thematic rubricator: UDC (Universal Decimal Classification) or other library and bibliographic classification and subject indexes;
    • List of references.
  8. “Offer” is the current agreement (an offer to the Author for the publication of an Article in the Journal).
  9. “Publication” is the process of placement of an Article in the Journal.
  10. “Article” is an article’s manuscript that has undergone the process of peer-review and editorial and publishing processing.
  11. “Editorial board” is the creative team that prepares the journal for publication.
  12. “Parties” refers to the Author and the Publisher.
  13. “Author Guidelines” are the requirements for Articles and additional materials to be published in the Journal (their design, structure, content, originality, ethics), placed in the “For authors” section of the Journal’s Internet website.

 

III. Subject of the Agreement (Offer)

  1. Under this Agreement, the Author transfers to the Publisher on a gratuitous basis for the entire term of validity of exclusive copyright provided for by the legislation of the Russian Federation, the exclusive (property) right to the Article created by the Author, including (but not limited to) the following rights:
    • Reproduction of the Article or its sections or parts, as well as the metadata of the Article in Russian and foreign languages, in any material form, including on paper and electronic media, as a separate work in Journals and/or databases (local or in the Internet) of the Publisher and/or other persons, at the discretion of the Publisher;
    • Distribution of the Article or its sections or parts, as well as the metadata of the Article in Russian or foreign languages, on any medium as part of the Journal and/or databases of the Publisher or other persons, at the discretion of the Publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author;
    • Making the Article or any of its sections or parts, as well as the Article’s metadata in Russian or foreign languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choice;
    • Granting permission/s for the use of the Article or its sections or parts, as well as its metadata in Russian or foreign languages, to third parties with notice to the Author made by posting relevant information on the Journal’s website, without paying remuneration to the Author;
    • Processing the Article, including translating to any languages and using the revised (translated) Article in the aforementioned ways.
  2. Other rights not directly transferred to the Publisher under this Agreement, including patent rights to any process, method etc., ideas or discoveries described by the Author in the Article, as well as trademark rights, will be retained by the Author.
  3. The terms and conditions of this Agreement, obliging the Publisher to publish the Article, on the transfer of the exclusive right to the Article to the Publisher, as well as the terms and conditions granting the Publisher and the Author the right to use the Article in accordance with the Agreement, will take effect only in case of acceptance of the Article for publication in the Journal (condition precedent). The moment of acceptance of the Article for publication in the Journal is the moment of sending the notification of acceptance of the Article for publication to the Author from the official e-mail of the Journal.
  4. The rights are transferred by the Author to the Publisher free of charge, publication of the Article in the Journal does not entail any financial obligations of the Publisher towards the Author.
  5. If the Editorial board decides to reject the Submission or refuse to publish the Article in the Journal (i.e., retraction of the published Article), this Agreement becomes invalid. The decision to refuse publication (retraction of the published Article) will be sent to the Author at the e-mail address specified in the Submission.

 

IV. Rights and Duties of the Parties

  1. The Author guarantees that:
    • He/she is a legal holder of the copyright to the materials submitted to the Publisher as part of the manuscript of the Article;
    • The rights transferred to the Publisher under this agreement have not been previously transferred and will not be transferred to third parties;
    • The manuscript of the Article contains all references to the cited authors and/or publications (materials) provided for under the current copyright legislation;
    • The Author has obtained all the necessary permissions for all deliverables, facts and other borrowed materials he/she holds no copyright to and that are used in the manuscript of the Article;
    • The Article manuscript contains only materials permitted to be published in the open press in accordance with the current legislative acts of the Russian Federation, and its publication and distribution will not lead to the disclosure of secret (confidential) information (including state secrets);
    • The Author has informed co-authors about the terms of this Agreement and has received their consent to execute this Agreement under the terms provided for in the Agreement.
  2. The Author undertakes:
    • To make amendments to the manuscript of the Article in accordance with the Author Guidelines posted on the Journal’s website and recommendations of the Editorial board;
    • Not to use an electronic copy of the Article for commercial purposes and in other journal publications without the consent of the Publisher;
  3. in the process of preparing a manuscript for publication, the Author undertakes:
    • To make corrections to the text of the manuscript that have been marked by the peer-reviewers and accepted by the Editorial board, and/or as necessary, upon the request of The Publisher and the Editorial board, finalize the manuscript of the Article;
    • In a timely manner (within the deadlines specified by the Editorial board) to review and coordinate the editorial revisions made to the manuscript (including answering the editors' questions), and proofread the made-up Article (original layout in PDF);
    • While proofreading, suggest only the minimum of corrections to the made-up Article in order to eliminate factual errors made.
  4. The Author has the right to:
    • Make changes to the Article (both during the review process and in the process of preparing the Article for publication and after publication);
    • Use preprint or prior-to publication electronic versions of an unpublished Article in the form and content accepted by the Publisher for publication in the Journal. Such prior-to-publish versions can be placed as electronic files on the personal websites of the Author (co-authors) or on the protected external websites of the employers of the Author; however, the Author cannot use the unpublished version(s) for commercial use or for systematic external distribution by a third party The author or co-authors must:
      • Include the following warning in the prior-to-publish version: “This is prior-to-publish version of the article accepted for publication in (Journal’s name), © Eco-Vector (year)”;
      • Provide the corresponding electronic link to the Publisher’s website at https://journals.eco-vector.com/ and/or via the DOI.
    • Copy or transfer a copy of the published Article in whole or in part to colleagues free of charge for their personal or professional use, for the promotion of academic or scientific research, or for informational purposes of the Author’s employer.
    • Use materials (including data, text, images, tables) from a published Article in a book written by any co-author or other non-periodical scientific or educational publication.
    • Use figures, tables, data and text excerpts from the Article for his or her own education purposes, or to include them in other works to be published in print or electronic format by a third party, or to submit them in electronic format on an internal computer network protected from uncontrolled use, or on the public website of the Author (co-authors) or his/her employer.
      f) Include the Article materials in educational and methodical works distributed free of charge within the educational process among students (cadets, graduate students, doctoral students) of the Author (co-authors) or to save the Article in electronic format on the local server for students' access (as to the methodical material necessary for mastering within the training), as well as for internal training programs in the institution of the Author's employer.
    • Withdraw the Submission for publication of the Article until the Editorial board of the Journal makes a final decision on the possibility of publication.
  5. The Publisher undertakes:
    • To carry out editorial and publishing preparation of the Article (copyediting and academic editing, formatting, bibliographic design, layout, proofreading, checking of corrections made, translation of the description of the Article or full-text translation – at the option of the Publisher) in accordance with the editorial standards of the Publisher and the original layout accepted at the time of publication;
    • To publish the Author’s article in the Journal in printed and electronic form in accordance with the terms of this Agreement;
    • If necessary, as so decided by the Journal’s Editorial board, to provide the Author with the made-up Article and make a reasonable editing;
    • To provide to the Author the unlimited access to the final electronic version of the published Article through the Author’s personal account on the Journal’s website from the date of publication of the corresponding issue of the Journal;
    • To comply with the copyrights as provided for by the current legislation, as well as protect them and take all necessary measures to prevent copyright infringement by third parties.
  6. The Publisher has a right to:
    • Make any decision on the Author's Submission for publication of the Article, including "accept for publication", "refuse to publish" and "recommend revision of the Article for re-evaluation" (the right to evaluate the Article and make decisions on publication of the Article is managed by the Editorial board of the Journal headed by the Editor-in-Chief);
    • Conduct an expert evaluation of the Article manuscript and invite the Author to make the necessary changes (revisions) to the manuscript. The Article will not be published in the Journal unless such changes are not made.
    • Independently determine the issue of the Journal for the publication of the Article, make decisions on the terms of publication and their changes, on the withdrawal of the Article and its retraction in cases stipulated by the Code of Ethics of the Publishing House (see details: https://eco-vector.com/Eco-Vector_Ethic_Policy.php);
    • Provide technical editing, copyediting of the Article’s manuscript without altering the main content;
    • Require from the Authors and all target audience of readers to indicate the correct reference to the final version of the Article published in the Journal (name of the Journal, Publisher, Author, title of the Article, issue number of the Journal and year of publication indicated in the Journal, DOI);
    • Post preliminary and/or advertising information about the upcoming publication of the Article in the media and other information sources;
    • Make changes to the Offer in accordance with the procedure established by the Offer.
  7. In all cases not stipulated and not provided for in this agreement, the parties are obliged to be guided by the relevant current laws of the Russian Federation.

 

V. Acceptance of the Offer and Execution of the Agreement. Validity of the Agreement

  1. The Author accepts the Offer by submitting the manuscript of the Article to the Publisher through the electronic manuscript submission system on the Journal's Internet website.
  2. Acceptance of the offer by the Author creates an Agreement in writing (Articles 438 and 1286.1 of the Civil Code of the Russian Federation) on the terms of the offer.
  3. This Agreement is valid for the duration of the exclusive rights to the Article.

 

VI. Procedure for changing and terminating the Agreement

  1. The Publisher has the right to unilaterally change the terms of this Agreement, in advance, at least ten (10) calendar days before the entry into force of the intended relevant changes, but with notice to the Author through the Journal’s website or by e-mail to the Author’s e-mail address specified in the Author’s Submission. The changes will take effect from the date specified in the relevant notification.
  2. If the Author rejects the changes to the terms of this Agreement, he/she has the right to notify the Publisher by sending a written notification through the online manuscripts submission system placed in the corresponding section of the Journal’s website on the Internet, or by sending a notification to the official e-mail address of the editorial office.
  3. This Agreement may be terminated prematurely, either by agreement of the parties at any time, or on other grounds provided for in this Agreement.
  4. The Author has the right to unilaterally withdraw from the execution of this Agreement by sending the Publisher a corresponding notification in writing at least sixty (60) calendar days in advance before the expected date of publication of the Article in the Journal.
  5. Termination of the Agreement for any reason does not release the parties from liability for any violation of the terms of the Agreement that occurred during the validity period.

 

VII. Responsibility

  1. The parties are responsible for non-fulfillment or improper fulfillment of their obligations under the Agreement in accordance with the current relevant legislation of the Russian Federation.
  2. All information provided by the Author must be reliable. The author is responsible for the accuracy and completeness of the information and guarantees he/she transfers to the Publisher. When using false information received from the Author, the Publisher is not responsible for the negative consequences caused by his actions on the basis of the false information provided.
  3. With regard to the content of the Article, the Author is solely responsible for compliance with the requirements of the laws of the Russian Federation pertaining to advertising, copyright and related rights’ protection, protection of trademarks and service marks, and the protection of consumer rights.
  4. The Publisher will have no liability under the agreement:
    • for any actions that are a direct or indirect result of Author’s illegal actions
    • for any loss incurred by the Author, regardless of whether the Publisher could have foreseen the possibility of such losses or not.
  5. The Publisher is released from liability for violation of the terms of the Agreement if such violation is caused by force majeure, including actions of state authorities (including the adoption of legal acts), fire, flood, earthquake, other natural disasters, lack of electricity and/or computer network failures, strikes, civil unrest, riots, and any other circumstances directly affecting the ability to fulfill the obligations of the Parties.

 

VIII. Dispute resolution

  1. Disputes and disagreements will be resolved by the Parties through negotiations, and in case of failure to reach an Agreement they will strive to seek resolution in accordance with the current legislation of the Russian Federation.
  2. If there are unresolved disagreements, the Parties agree to resolve the disputes in court at the location of the Publisher in accordance with the current legislation of the Russian Federation.

 

IX. Miscellaneous

  1. All notifications, messages, requests, etc. (with the exception of documents that must be sent as originals in accordance with the laws of the Russian Federation) are considered received by the Author if they were transmitted (sent) by the Publisher through the Journal’s website (including by publication), by e-mail and other communication channels specified in the Submission, and other communication channels. The parties recognize the legal force of notifications, messages, requests, etc., transmitted (sent) by the above methods.
  2. In the event of claims against the Publisher related to the violation of the exclusive copyright and other intellectual property rights of third parties when creating an Article or in connection with the execution of this Agreement by the Author, as well as in connection with the use of the Article by the Publisher in accordance with the Agreement, the author undertakes:
    • To immediately take measures to resolve disputes with third parties soon after receiving Publisher’s notification, and if necessary, enter into legal proceedings on the Publisher’s side and take all appropriate actions needed to exclude the Publisher from the list of defendants;
    • To reimburse the Publisher for the court costs incurred, expenses and losses caused by the application of measures to secure the claim and execute a court decision, and the amounts paid to a third party for the violation of exclusive copyright and other intellectual property rights, as well as other losses incurred by the Publisher in connection with the Author’s non-compliance with the guarantees provided by them under this Agreement.

 

X. Legal address and details of the Publisher

  • Eco-Vector
  • Address: 191186, St. Petersburg, Aptekarsky Pereulok, 3 letter A, room 1N
  • TIN: 7806423692; KPP: 784101001; OGRN: 1099847039907.

 

Privacy Statement

The editorial Board of the journal and the administration of the website of the journal do not transfer personal information to third parties, except for those cases and to the extent specified in the terms of the copyright agreement.

The affiliation work and e-mail address of the authors of the manuscript accepted for publication will be published in the section "information about the authors" of the printed version of the journal and in the section "about the authors" on the page of the article on the website of the journal.

The phone number of the corresponding author will be accessible only to the Editorial Board Secretariat and will only be used in cases of emergency.

 

Author Fees

General information about paid services available to the authors of the journal

The review of the author's manuscripts submitted for publication in the journal is carried out on a fee basis.

Payment for the review of the manuscript does not guarantee the publication of the article and provides the editorial board with complete freedom to select materials for publication in the journal.

Manuscripts approved by the editorial board are published without charging additional fees to the authors.

The fee for reviewing the manuscript does not lead to the formation of any financial interest of the editorial staff in the number of published articles and, therefore, does not reduce the quality of the selection of manuscripts.

In addition to paying for the review of the manuscript, the publisher offers the authors a number of additional paid services, the choice of which also does not affect the outcome of the review of the manuscript and the decision of the editorial board to publish the article.

The editor-in-chief has the right to compile a list of categories of authors:

  1. The publication fee is not charged
  2. Eligible for a discount

 

Fast-Track:

Price: 1100.00 (USD)

Optional payment

The Fast-Track protocol allows authors to request an extremely fast peer-review based evaluation of an article and to receive a final decision within 21 days.

For the Fast-Track users:

  • the guaranteed final decision time is 21 days, starting the count from the first business day on which valid payment information has been received from the submitting author; Authors will receive a report with peer-review results and a decision letter from the Editor-in-Chief and the Editorial Board;
  • in case of manuscript acceptance by Editor-in-Chief and Editorial Board members (in regards with positive peer-reviews) — the guaranteed publication is a nearest upcoming issue of the journal and Online First publication ASAP.

More information about activating the Fast-Track protocol is available here.

Article Publication Charge:

Price: 24000.00 (USD)

Mandatory Payment

An article publication charge (APC) is a fee charged to authors to make their work available online. This fee may be paid by the author, the author’s institution, or their research funder. The journal charges an APC to cover the costs involved in the publication process, from administrating peer-review to copyediting and hosting the final article on dedicated servers. 

Authors are only eligible to pay an APC only after receiving official notification from the editors that their article has been accepted for publication.

For more information on the terms and payment options for article publication, click here.

Immediate Open Access:

Price: 700.00 (USD)

Optional Payment

The journal is available for subscribrs, but authors can make their articles available in Open Access and influence the distribution of published work to the global professional community (more information about Open Access can be found in the WIKI).

An open access publication charge (OAPC) is a fee charged to authors to make their work available as open access (OA). This fee may be paid by the author, the author’s institution, or their research funder. The journal charges an APC to cover the costs involved in the publication process, from administrating peer-review to copy editing and hosting the final article on dedicated servers. 

Articles published in OA will be distributed under the terms of the CC BY-NC-ND 4.0 license, without an embargo period or any other restrictions.

More information about the Optional Open Access service is available here.

Waiver policy

An author's team can apply to the Editor-in-Chief for the APC cancellation or for a discount. We don't want the need for payment to become a barrier to publishing high-quality work in our journal.

To receive a discount, a member of the author team should submit a written collective request to the publisher for a discount on the APC, along with a justification for their request.

The decision on whether to grant a discount and its amount is made jointly by the editor-in-chief and the publisher's management based on the author's request. If the discount is approved, authors will be informed of the final cost and further payment instructions.

Discounts are available for all paid publishing services (open access publication, Fast-Track protocol, APC) as part of the Peer-Reviewer Rewards Program.